113. 筋ジストロフィー Muscular dystrophy Clinical trials / Disease details

臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170

7 trials found

diseases per page:

Showing 1 to 7 of 7 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2022-000389-16-ES (EUCTR)	14/07/2022	15/07/2022	A Phase 3 study to determine the Efficacy and Safety of LosmapimodinTreating Patients with Facioscap ...	A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the ...	Facioscapulohumeral Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10064087;T ...	Product Name: Losmapimod Product Code: FTX-1821 INN or Proposed INN: Losmapimod	Fulcrum Therapeutics	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	230	Phase 3	France;United States;Canada;Spain;Denmark;Germany;Netherlands;United Kingdom;Italy
2	NCT05397470 (ClinicalTrials.gov)	June 16, 2022	4/5/2022	Efficacy and Safety of Losmapimodin Treating Patients With Facioscapulohumeral Muscular Dystrophy (F ...	A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the ...	Facioscapulohumeral Muscular Dystrophy (FSHD)	Drug: Losmapimod;Drug: Placebo oral tablet	Fulcrum Therapeutics	NULL	Recruiting	18 Years	65 Years	All	230	Phase 3	United States;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom
3	NCT04264442 (ClinicalTrials.gov)	February 13, 2020	30/1/2020	Efficacy and Safety of Losmapimodin Treating Subjects With Facioscapulohumeral Muscular Dystrophy (F ...	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Effica ...	Facioscapulohumeral Muscular Dystrophy (FSHD)	Drug: Losmapimod	Fulcrum Therapeutics	NULL	Active, not recruiting	18 Years	65 Years	All	76	Phase 2	United States;Canada;France;Spain;Germany
4	EUCTR2019-001181-15-ES (EUCTR)	29/10/2019	29/10/2019	Safety and Efficacy of Losmapimod in Patients with FSHD	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 24-Week, Parallel-Group Study of the Effica ...	Facioscapulohumeral Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10064087;T ...	Product Name: Losmapimod Product Code: FTX-1821 INN or Proposed INN: LOSMAPIMOD	Fulcrum Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	66	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	France;United States;Spain;Germany
5	EUCTR2019-001181-15-FR (EUCTR)	17/09/2019	29/05/2019	Safety and Efficacy of Losmapimod in Patients with FSHD	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 24-Week, Parallel-Group Study of the Effica ...	Facioscapulohumeral Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10064087;T ...	Product Name: Losmapimod Product Code: FTX-1821 INN or Proposed INN: LOSMAPIMOD	Fulcrum Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	66	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	United States;France;Spain;Germany
6	NCT04004000 (ClinicalTrials.gov)	August 23, 2019	25/6/2019	Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Los ...	An Open-Label Pilot Study of Losmapimodto Evaluate the Safety, Tolerability, and Changes in Biomarke ...	Facioscapulohumeral Muscular Dystrophy 1	Drug: Losmapimod	Fulcrum Therapeutics	NULL	Active, not recruiting	18 Years	65 Years	All	14	Phase 2	Netherlands
7	NCT04003974 (ClinicalTrials.gov)	August 9, 2019	25/6/2019	Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Effica ...	Facioscapulohumeral Muscular Dystrophy (FSHD)	Drug: Losmapimod;Drug: Placebo oral tablet	Fulcrum Therapeutics	NULL	Completed	18 Years	65 Years	All	80	Phase 2	United States;Canada;France;Spain;Germany

First Previous1Next Last